Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 225 of 1048 entries
View as:

Distinct Metastatic Phenotypes Between Early-onset and Late-onset Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06040021 Org: User:
Start: 01/01/08 End: 06/30/23 Due: 06/30/24

Stage I HER2 Positive Invasive Breast Cancer De-escalation Study(IRIS)

Phase: N/A Priority: Normal
NCT ID: NCT04383275 Org: User:
Start: 08/23/21 End: 05/15/27 Due: 05/15/28

Camrelizumab Plus Pyrotinib Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Phase: N/A Priority: Normal
NCT ID: NCT05111444 Org: User:
Start: 12/31/21 End: 06/30/24 Due: 06/30/25

A Study of Famitinib Malate in HER2-negative Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01653574 Org: User:
Start: 05/31/12 End: 11/30/13 Due: 11/30/14

Comparison of Kimura Versus Warshaw Technique for Laparoscopic Spleen-Preserving Distal Pancreatectomy

Phase: N/A Priority: Normal
NCT ID: NCT06167421 Org: User:
Start: 01/01/24 End: 12/31/27 Due: 12/31/28

Fluzoparib Combined With Dalpiciclib for Platinum Resistant Recurrent Ovarian Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06552858 Org: User:
Start: 09/01/24 End: 01/31/27 Due: 01/31/28

Neoadjuvant Radiation in Locally Advanced Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05479409 Org: User:
Start: 03/01/21 End: 12/31/25 Due: 12/31/26

Combination of Chidamide and Fulvestrant for HR+/HER2- Breast Cancer That Has Failed Previous CDK4/6 i Adjuvant Therapy

Phase: N/A Priority: Normal
NCT ID: NCT05806047 Org: User:
Start: 05/01/23 End: 11/01/24 Due: 11/01/25

Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06121700 Org: User:
Start: 01/01/23 End: 12/31/27 Due: 12/31/28

Mediastinal Staging Accuracy of a Selective Lymphadenectomy Strategy in Early Stage NSCLC (ECTOP-1003)

Phase: N/A Priority: Normal
NCT ID: NCT03216551 Org: User:
Start: 03/14/19 End: 05/30/22 Due: 05/30/23

Perioperative Chemoimmunotherapy With/Without Preoperative Chemoradiation for Locally Advanced Gastric Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05161572 Org: User:
Start: 09/28/21 End: 09/30/22 Due: 09/30/23

Tislelizumab Combined With Sitravatinib as Consolidation Treatment Following Concurrent Chemoradiation in Patients With Locally Advanced, Unresectable NSCLC

Phase: N/A Priority: Normal
NCT ID: NCT05176925 Org: User:
Start: 01/10/21 End: 09/28/22 Due: 09/28/23

PD-1 Combined With Adjuvant Chemotherapy and Antivascular Therapy Versus Chemotherapy Alone in Patients With Operable Triple-negative Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05862064 Org: User:
Start: 06/01/23 End: 07/01/28 Due: 07/01/29

Neoadjuvant Chemo-endocrine Therapy Versus Chemotherapy Alone in ER-positive, HER2-negative Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02980965 Org: User:
Start: 05/31/13 End: 02/28/17 Due: 02/28/18

A Study of Radiotherapy Combined With Raltitrexed and Irinotecan in Metastatic or Locally Recurrent Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04499586 Org: User:
Start: 01/01/19 End: 12/01/20 Due: 12/01/21

Circulating Tumor DNA Methylation Guided Postoperative Follow-up Strategy for Non-metastatic Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05904665 Org: User:
Start: 06/15/23 End: 06/30/28 Due: 06/30/29

Endostar Combined With CHOP Regimen as First Line Chemotherapy for Peripheral T Cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT00974324 Org: User:
Start: 08/31/09 End: 09/30/11 Due: 09/30/12

The Effect of Intervention With Probiotic K56 on Body Fat Reduction in Obese Subjects

Phase: N/A Priority: Normal
NCT ID: NCT05192811 Org: User:
Start: 11/18/21 End: 12/01/22 Due: 12/01/23

Detecting Hypotension By Continuous Non-invasive Arterial Pressure Monitoring

Phase: N/A Priority: Normal
NCT ID: NCT02532270 Org: User:
Start: 09/30/15 End: 06/30/16 Due: 06/30/17

Second-Line Adjuvant Therapy With Nab-Paclitaxel Plus Gemcitabine Versus Oxaliplatin Plus Folinic Acid and Fluorouracil for Gemcitabine-Refractory Pancreatic Cancer After Curative Resection

Phase: N/A Priority: Normal
NCT ID: NCT02506842 Org: User:
Start: 06/30/15 End: 06/30/19 Due: 06/30/20

SBRT for Oligo-residual NSCLC After Treatment With PD-1/PD-L1 Immune Checkpoint Inhibitors

Phase: N/A Priority: Normal
NCT ID: NCT04767009 Org: User:
Start: 01/01/21 End: 12/31/25 Due: 12/31/26

Phase II Study of Postoperative Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma (ESO- Shanghai 17)

Phase: N/A Priority: Normal
NCT ID: NCT04764227 Org: User:
Start: 05/30/20 End: 03/30/27 Due: 03/30/28

Intraperitoneal Injection of Oncolytic Viruses H101 for Patients With Refractory Malignant Ascites

Phase: N/A Priority: Normal
NCT ID: NCT04771676 Org: User:
Start: 03/05/21 End: 01/31/23 Due: 01/31/24

Radiofrequency Ablation Combined With S-1 for Pancreatic Cancer With Liver Metastasis

Phase: N/A Priority: Normal
NCT ID: NCT02634502 Org: User:
Start: 10/31/13 End: - Due: -

Mutation of BRCA1/2 and Other Potential Genes in Triple-negative Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02670668 Org: User:
Start: 01/31/16 End: 12/31/18 Due: 12/31/19